Article

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for Tivozanib

2024-04-09

Abstract excerpt

<title>Abstract</title> <p>This study analyzes adverse drug events (ADEs) associated with Tivozanib, sourced from the Food and Drug Administration Adverse Event Reporting System (FAERS) database. We collected ADE data for Tivozanib from 2021 Q2 through 2023 Q4. Post-standardization, we employed several signal quantification methods for analysis, such as the Reporting Odds Ratio (ROR), Proportional Reporting Ratio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bbc91307-4ef1-588f-bbb5-90d063e1cdc5
DOI: 10.21203/rs.3.rs-4171107/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibDOI 10.21203/rs.3.rs-4171107/v1Read

Real-world safety profile of Enfortumab Vedotin: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read

Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity Read

A real-world pharmacovigilance study of brentuximab vedotin based on the FAERS database from 2011 to 2024Semantic proximity Read

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read

Real-world pharmacovigilance study of voclosporin based on FAERS and VigiBaseSemantic proximity Read

Real-world safety of zonisamide: Mining and analysis of adverse events related to zonisamide based on FAERS databaseSemantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Gastrointestinal adverse events associated with Riociguat: A pharmacovigilance study based on FDA adverse event reporting systemSemantic proximity Read

Immune-related adverse-event signals of durvalumab: cross-database pharmacovigilance analysis of WHO-VigiAccess and FAERS with comparative assessment versus atezolizumabSemantic proximity Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Analysis and Mining of Baloxavir Marboxil Adverse Event Signals in Elderly Patients Based on the FAERS DatabaseSemantic proximity Read

Analysis and Mining of Baloxavir Marboxil Adverse Event Signals in Elderly Patients Based on the FAERS DatabaseSemantic proximity Read